


PATIENT		SAMPLE		ORDERING PHYSICIAN	
Name:		Specimen ID:	MDX-PT-26	Name:	
ID:		Date of collection:		Address:	
Report date:		Type:	Metastatic	Contact:	

TEST DESCRIPTION

The **Multiplex8+** breast cancer test assesses RNA-based biomarkers by conducting a **VISUALIZATION TEST** that uses RNA fluorescent in situ hybridization (RNA-FISH) to visualize a panel of biomarkers. Based on the expression of these biomarkers and the tissue histology, laser capture microdissection is used to dissect out regions of interest. With these tumor-enriched samples, a **SEQUENCING TEST** that utilizes total RNA next generation sequencing to survey gene expression in a spatially resolved manner, is further carried out. Analytical validation of **Multiplex8+** was conducted on a large retrospective cohort of 1 080 breast tumors.



THE TEST PROVIDES INFORMATION ABOUT:

- RECEPTOR STATUS:** for RNA expression of the estrogen receptor, progesterone receptor, Her2 receptor, and Ki67 measured and cross-validated by the two tests.
- MOLECULAR SUBTYPE:** based on RNA gene expression tumor biology.
- GENE SIGNATURES:** personalized for patients' tumor biology and clinical status.

A SUMMARY IS PROVIDED BELOW AND ADDITIONAL DETAILS ARE PROVIDED IN THE FOLLOWING PAGES

RESULTS SUMMARY

RECEPTOR STATUS

Sample	ESR1	PGR	ERBB2	MKI67
A (primary)	+	+	-	+
B (recurrence)	-	-	- Low	+


MOLECULAR SUBTYPE

Intrinsic subtype	TNBC subtype
Luminal B	-
Her2+	-

RELEVANT TREATMENT

THERAPY	KEY FINDINGS	CLINICAL BENEFIT
Sacituzumab govitecan (Trodelvy)	Gene expression	Predicted benefit (both Sample A and B)
Veliparib, Carboplatin	Gene expression, gene expression signatures	Predicted benefit (both Sample A and B)
Trastuzumab deruxtecan (Enhertu)	Molecular subtype, gene expression, gene expression signatures	Predicted benefit (Sample B)

LASER CAPTURE MICRODISSECTION



Based on histological assessment and RNA-FISH biomarker expression, two samples were laser capture microdissected for further analysis.

Sample A (red outline)

Sample B (yellow outline)

MOLECULAR SUBTYPE

Intrinsic subtype	TNBC subtype ²⁻⁴
Luminal B	-
Her2+	-

INTERPRETATION

- The biology of luminal B and Her2+ tumor types is consistent with immunohistochemical and clinical designation.
- Luminal B tumors are generally ER+, but may have variable ER/PR expression, and they can be either Her2+ or Her2-. Relative to luminal A tumors, they may have higher grade, proliferative activity, poorer outcomes, and consequently may require chemotherapy in addition to endocrine therapy.
- The Her2-enriched subtype (Her2+) is characterized by overexpression of Her2 and its downstream signaling pathways. Her2+ breast cancer has a poorer prognosis than luminal breast cancers and generally responds to anti-Her2 targeted therapies.

GENE SIGNATURE

- Based on the assigned molecular subtype, and TNBC subtype (if applicable), we evaluated several individual genes and gene signatures that demonstrate prognostic and predictive potential in early and advanced/metastatic settings.

Treatment type/ Pathway	Gene signature	Description	Sample A Percentile	Sample B Percentile
Prognosis	Consensus prognostic signature	The prognostic signature is derived from a consensus of three research-based prognostic signatures, including the 21-gene signature GENE21 ⁵ , the 70-gene GENE70 signature ⁶ , and the 50-gene risk of relapse based on subtype alone (ROR-S) signature ⁷ . The prognostic signatures are intended for early-stage breast cancer patients with ER+/Her2- IHC, lymph node-negative, or 1-3 positive lymph nodes. The score is reported as high, intermediate, or low. Patients with high signature scores are at a greater risk of relapse and may benefit from adjuvant chemotherapy, while patients with low scores have lower risk of relapse and may not benefit from adjuvant chemotherapy.	N/A	N/A

RECEPTOR STATUS

Sample	ESR1	PGR	ERBB2	MKI67
A (primary)	+	+	-	+
B (recurrence)	-	-	- Low	+

Receptor status was determined using both the **VISUALIZATION TEST** and **SEQUENCING TEST**: the table shows results after cross-validation.

INTERPRETATION

- The results from both RNA-FISH and RNA-SEQ are concordant with the immunohistochemistry findings.
- According to the **SEQUENCING TEST**, ERBB2 (HER2) expression in sample B is low (HER2-low), therefore this patient may benefit from treatment with trastuzumab deruxtecan (Enhertu).

Based on the **SEQUENCING TEST**, we used a consensus subtyping approach consisting of our proprietary 293 gene molecular subtyping signature, a research-based PAM50 test and the AIMS method to classify the intrinsic molecular subtype ¹. TNBC subtype, if applicable, was classified according to Lehmann ²⁻⁴.

GENE SIGNATURE

Treatment type/ Pathway	Gene signature	Description	Sample A Percentile	Sample B Percentile
Luminal signatures	ESR1	The ESR1 and PGR genes encode for the estrogen (ER) and progesterone (PR) hormone receptors, respectively, which are involved in growth, metabolism, and reproductive functions. High ER/PR is predictive of endocrine therapies and low or negative ER/PR is associated with poor prognosis ⁸ .	Medium (45%)	Low (16%)
	PGR		Medium (41%)	Low (13%)
	ESR1_PGR average	The average gene expression of ESR1 and PGR. Higher levels of hormone receptors are predictive markers for endocrine therapies.	Medium (37%)	Low (13%)
	E2F4_score	This gene signature assesses activity of the E2F4 transcription factor and its targets. A high E2F4 signature is associated with endocrine resistance to aromatase inhibitors and may predict sensitivity to CDK4/6 inhibitors ⁹ .	High (72%)	Medium (65%)
Her2	ERBB2	The ERBB2 gene is translated into Her2, a receptor tyrosine kinase involved in cell growth/proliferation and is both a prognostic marker and predictive of response to Her2 targeted therapies ⁸ .	Low (2%)	Medium (56%)
	MUC4	Mucin 4 (MUC4) is a glycoprotein that is implicated in resistance to trastuzumab through interactions with the Her2 receptor. High MUC4 is associated with reduced sensitivity to trastuzumab ¹⁰ .	Medium (59%)	Low (28%)
	NRG1	NRG1 codes for neuregulin 1, a ligand of the Her3 receptor. In the phase II NeoSphere trial, high NRG1 gene expression was associated with reduced response to neoadjuvant trastuzumab, but not combination trastuzumab-pertuzumab ¹¹ .	Medium (66%)	Low (14%)
	pSTAT3-GS	A signature that predicts phosphorylation of STAT3 and was found to be predictive of trastuzumab resistance in the FinHer study ¹² .	High (71%)	Low (7%)
	Her2 amplicon_MDX	Proprietary MDX 43-gene signature used to assess Her2 status.	Low (2%)	Low (1%)
	Module7_ERBB2	Her2-signaling signature predictive of response to multiple anti-Her2 treatments in the I-SPY2 trial ¹³ .	Low (2%)	Low (3%)
Proliferation	AURKA	Aurora Kinase A (AURKA) is a protein coding gene involved in cell proliferation and is an independent prognostic marker in breast cancer.	Medium (53%)	Medium (39%)
	MKI67	MKI67 codes for the marker of proliferation Ki67 protein, a marker of poor prognosis in ER+/Her2- tumors, but not Her2+ or TNBC tumors. Ki67 levels are also predictive of sensitivity to neoadjuvant endocrine and chemotherapies ⁸ .	Medium (65%)	High (91%)
	Module11_proliferation	Proliferation index used in I-SPY2 trial broadly predictive of pathological complete response in hormone receptor positive patients ⁴ .	Medium (61%)	Medium (55%)
	Proliferation_MDX	Proprietary MDX 7-gene signature used to assess cellular proliferation and cross-validate MKI67 expression levels.	Medium (47%)	High (78%)
CDK4/6 inhibitors	CDK4	Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) are important proteins that regulate cell cycle progression from G1 to S phases. They are the main targets of CDK4/6 inhibitors such as palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio); however, it is unclear whether their expression level predicts CDK4/6 inhibitor sensitivity.	Medium (64%)	High (77%)
	CDK6		High (71%)	Low (20%)
	CCNE1	Elevated expression of the G1/S cell cycle regulators, CCNE1, CCND3, and CDKN2D, was associated with resistance to palbociclib (Ibrance) in the single-arm phase II neoadjuvant trial (NeoPalAna) ¹⁴ .	Low (12%)	Medium (47%)
	CCND3		High (73%)	Medium (60%)
	CDKN2D		Low (21%)	Low (6%)
PIK3CA mutations	PIK3CA-GS	A gene signature that is predictive of mutations in the PIK3CA gene and consequently the PI3K inhibitor alpelisib (Piqray). A high PIK3CA-GS score is also associated with activation of the PI3K/AKT pathway and loss of mTORC1 signaling, which may be relevant for response to mTOR inhibitors (e.g., everolimus) ¹⁵ .	Low (18%)	Low (8%)

GENE SIGNATURE

Treatment type/ Pathway	Gene signature	Description	Sample A Percentile	Sample B Percentile
Chemotherapy	TOP1	The gene encoding DNA topoisomerase I, an enzyme critical for DNA transcription, is a target for anticancer drugs.	Medium (48%)	High (97%)
	TOP2A	The gene encoding DNA topoisomerase IIa, an enzyme critical for DNA transcription, is a target for anticancer drugs.	Low (22%)	Low (25%)
	RAD51	The DNA repair protein RAD51 homolog 1 (RAD51) is involved in the repair of damaged DNA and is associated with resistance to chemotherapy.	Medium (66%)	High (71%)
	ERCC1	The DNA excision repair protein ERCC-1 (ERCC1) is involved in the repair of DNA damage and is associated with resistance to chemotherapy.	Medium (42%)	Medium (56%)
	TYMS	The Thymidylate Synthetase (TYMS) gene encodes a protein involved in DNA biosynthesis and is the target of the antimetabolite chemotherapy, 5-Fluorouracil ¹⁶ .	Low (22%)	Low (19%)
	SLC29A1	SLC29A1 codes for the equilibrative nucleoside transporter 1 (ENT1) protein, which is a nucleoside transporter that is involved in transporting gemcitabine and capecitabine ¹⁷ .	Medium (42%)	Low (25%)
	DHFR	Dihydrofolate reductase is an enzyme coded by the DHFR gene and is involved in folate metabolism and cell growth. It is the target of the antimetabolite chemotherapy, methotrexate ¹⁸ .	Medium (38%)	Medium (55%)
	SLC19A1	SLC19A1 codes for the reduced folate carrier 1 (RFC1) protein, which transports methotrexate into the cell ¹⁸ .	Low (26%)	Low (18%)
	CDK12	The protein product of the Cyclin Dependent Kinase 12 (CDK12) gene regulates transcription, DNA repair pathways, and cell cycle ¹⁹ .	Low (3%)	Low (4%)
	MAPs_Mitotic_kinases_neoadj_chemo118	A 118-gene signature predicting response to neoadjuvant taxane chemotherapy ²⁰ .	Medium (39%)	Low (15%)
	MAPs_Mitotic_kinases_neoadj_chemo17	A 17-gene signature predicting response to neoadjuvant taxane chemotherapy ²⁰ .	Medium (52%)	Medium (39%)
	Early_Relapse_ER.Neg	Chemoresistance gene signature predicting early relapse in ER-negative (ER-) patients after taxane-anthracycline chemotherapy ²¹ .	Medium (62%)	Medium (62%)
	Residual_disease_ER.Neg	Chemoresistance gene signature predicting residual disease in ER-negative (ER-) patients after taxane-anthracycline chemotherapy ²¹ .	Low (16%)	Low (3%)
	Pathologic_response_ER.Neg	Chemosensitivity gene signature predicting pathological complete response in ER-negative (ER-) patients after taxane-anthracycline chemotherapy ²¹ .	Medium (56%)	High (81%)
	Early_Relapse_ER.Pos	Chemoresistance gene signature predicting early relapse in ER-positive (ER+) patients after taxane-anthracycline chemotherapy ²¹ .	High (91%)	High (69%)
	Residual_disease_ER.Pos	Chemoresistance gene signature predicting residual disease in ER-positive (ER+) patients after taxane-anthracycline chemotherapy ²¹ .	High (78%)	High (80%)
	Pathologic_response_ER.Pos	Chemosensitivity gene signature predicting pathological complete response in ER-positive (ER+) patients after taxane-anthracycline chemotherapy ²¹ .	Medium (40%)	Medium (42%)

GENE SIGNATURE

Treatment type/ Pathway	Gene signature	Description	Sample A Percentile	Sample B Percentile
Immune system	PDCD1	PDCD1 codes for the immune checkpoint marker PD-1. PD-1 is the target of pembrolizumab (Keytruda), an immunotherapy approved for the first-line treatment of metastatic TNBC.	Medium (51%)	Low (17%)
	CD274	CD274 codes for the immune checkpoint marker PD-L1. PD-L1 is the target of atezolizumab (Tecentriq), an immunotherapy approved for approved for the first-line treatment of metastatic TNBC.	High (72%)	Medium (60%)
	CTLA4	Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) is an immune checkpoint marker and the target of several immunotherapies such as durvalumab (Imfinzi).	Medium (34%)	Low (9%)
	Module5_ TcellBcell	Immune signatures predictive of response to pembrolizumab in TNBC patients enrolled in (I-SPY2 trial) ¹⁴ . All signatures, with the exception of Mast_cells, were associated with increased probability of achieving pathological complete response.	High (75%)	Medium (35%)
	Chemokine12		High (78%)	Medium (53%)
	STAT1		High (68%)	Medium (53%)
	Dendritic_cells		High (72%)	Low (27%)
Mast_cells	High (84%)		High (97%)	
DNA damage and repair	VCpred_TN	DNA damage repair / immune signature predictive of response to veliparib (PARP inhibitor) and carboplatin (I-SPY2 trial) ¹⁴ .	High (71%)	High (78%)
Angiogenesis/ hypoxia	VEGFA	A gene coding for vascular endothelial growth factor, a protein involved in angiogenesis, vasodilation, and endothelial cell growth. VEGF is the target of the drug bevacizumab (Avastin).	Medium (44%)	Medium (38%)
	Hypoxia / Angiogenesis / Inflammatory_ MDX	Proprietary MDX 7-gene signature used to assess hypoxia, angiogenesis, and inflammation. Signature includes genes known to be predictive of response to bevacizumab (Avastin) in the neoadjuvant GeparQuinto trial ²² .	Low (24%)	Low (25%)
ADC (antibody- drug conjugate) targets	ERBB2	ERBB2 codes for the protein receptor Her2, which is a target for classical anti-Her2 treatments. Low and ultralow levels of Her2 can be eligible for treatment with the antibody-drug conjugate, trastuzumab deruxtecan (Enhertu) ²³ .	Low (2%)	Medium (56%)
	TACSTD2	TACSTD2 codes for Tumor-associated calcium signal transducer 2, also called Trop-2, which is the target of sacituzumab govitecan (Trodelvy), an antibody-drug conjugate approved for metastatic TNBC ²⁴ .	High (74%)	Medium (43%)
	NECTIN4	Nectin Cell Adhesion Molecule 4 (NECTIN4) is a cell adhesion molecule that is a target for antibody-drug conjugates in clinical trials for breast cancer.	Low (6%)	Low (6%)
	ERBB3	ERBB3 codes for a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. It is under investigation in clinical trials for the antibody-drug conjugate patritumab deruxtecan.	Low (13%)	High (80%)
	FOLR1	FOLR1 encodes the protein Folate Receptor Alpha, which is an antibody-drug conjugate target under investigation for the treatment of metastatic TNBC in several phase 1 and 2 clinical trials.	Low (14%)	Low (14%)
	F3	F3 codes for tissue factor, coagulation factor III a target of several antibody-drug conjugates in phase 1 clinical trials.	High (81%)	High (77%)
	SLC39A6	The SLC39A6 genes encodes for the zinc transporter LIV-1, which is highly expressed in luminal breast cancers and is under investigation in several phase 1 and 2 clinical trials.	Low (18%)	Medium (60%)
TPBG	The trophoblast glycoprotein (TPBG) is overexpressed in many breast cancers and is the target of at least two antibody-drug conjugates undergoing phase 1 clinical trials.	Medium (58%)	Medium (65%)	

Treatment type/ Pathway	Gene signature	Description	Sample A Percentile	Sample B Percentile
	ROR2	A gene that encodes the Receptor Tyrosine Kinase Like Orphan Receptor 2 protein, a target of the antibody-drug conjugate (Ozuriftamab Vedotin (BA3021/CAB-ROR2-ADC) that is under investigation in a phase clinical trial for advanced solid cancers, including TNBC.	Medium (40%)	Low (5%)
	CD276	This gene codes for an immune checkpoint marker called CD276 (also known as B7-H3). It is the target of the antibody-drug conjugate (Mirzotamab clezutoclax (ABBV-155) that is in a phase 1 and 2 clinical trial for advanced solid cancers, including breast cancer.	Medium (53%)	Low (19%)
	VTCN1	V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1 also called B7-H4) is an immune checkpoint marker and the target of the antibody-drug conjugate, SGN-B7H4V, which is under investigation in a phase1 clinical trial for advanced solid cancers, including breast cancer.	High (86%)	High (67%)
	CEACAM5	A gene that encodes CEA Cell Adhesion Molecule 5 protein, a target of the antibody-drug conjugate Tusamitamab ravtansine (SAR408701) that is under investigation in a phase 2 clinical trial for advanced solid cancers, including breast cancer.	Low (23%)	Medium (42%)

INTERPRETATION AND RECOMMENDATIONS

- Both samples have high (Sample A) to moderate (Sample B) expression of TACSTD2. TACSTD2 codes for Trop-2, which is the drug target of sacituzumab govitecan (Trodelvy), an ADC approved for the treatment of metastatic TNBC. In the biomarker analysis of the pivotal phase III ASCENT trial, patients with high/medium expression of Trop-2 benefited from sacituzumab govitecan. The cytotoxic payload of this ADC, SN-38, targets TOP1, which is expressed at moderate (Sample A) to high (Sample B) levels in both samples. Expression of both the ADC target and cytotoxic payload target suggest that sacituzumab govitecan may be effective in the advanced/metastatic setting for both Samples A and B.
- Both samples have high VCpred_TN signature scores. The I-SPY2 trial demonstrated that high VCpred_TN signature score, which reflects DNA repair deficiency and immune activation, predicts response to veliparib and carboplatin in the TNBC arm. This finding was further validated in the BrightNess trial. Sample A also has a high STAT1 and moderate Module11_proliferation signatures, which were also shown to predict benefit to veliparib and carboplatin in the ER+/Her2- arm of I-SPY2. However, it is important to note that high level of RAD51 may indicate resistance to chemotherapy and PARP inhibitors.
- Based on our retrospective cohort of 1080 breast tumors, ERBB2 expression in metastatic tissue (Sample B) is Her2-low. If appropriate for the patient, it is advised to explore treatment options with trastuzumab deruxtecan (Enhertu), which demonstrated efficacy in the DESTINYBreast04 study in patients with low Her2 expression (Her2-low). High expression of TOP1, the drug target of deruxtecan (97th percentile) further supports trastuzumab deruxtecan as a putative beneficial therapy. Patients with negative Her2 (or ultra-low Her2) also show benefit from trastuzumab deruxtecan.
- For the ER+ sample A, a high E2F4 signature score suggests potential resistance to aromatase inhibitors. A retrospective analysis of the Pre-Operative Palbociclib (POP) trial showed that palbociclib reduced the E2F4 signature, suggesting these individuals may respond to CDK4/6 inhibitors alone or in combination with endocrine therapy⁹. A potential benefit of CDK4/6 inhibitors for Sample A is supported by low expression of CDK4/6 inhibitor resistance markers (e.g., CCNE1 and CDKN2) and moderate expression of proliferation markers. Although Sample B shares some of these markers, it is uncertain if CDK4/6 inhibitors would be beneficial because the POP trial only contained patients with ER+ tumors.
- Sample B had high levels of ERBB3 (80th percentile), which is the drug target of patritumab deruxtecan, an ADC being studied in TNBC. The cytotoxic payload of this ADC, deruxtecan, targets TOP1 (97th percentile). The high levels of ADC targets and cytotoxic payload targets suggest that patritumab deruxtecan may be effective if the patient were enrolled in clinical trials using this ADC. Both samples also contain high expression of the ADC target F3 and high/moderate expression of the ADC target VTCN1, both undergoing clinical trials.

REFERENCES

- Gendoo, D.M.A. et al. *Bioinformatics* 32(7): 1097–1099 (2016).
- Lehmann, B. D. et al. *J Clin Invest* 121: 2750–2767 (2011).
- Lehmann, B. D. et al. *PLoS One* 11: e0157368 (2016).
- Bareche, Y. et al. *Ann Oncol* 29: 895–902 (2018).
- Paik, S. et al. *N Engl J Med* 351(27): 2817–2826 (2004).
- van't Veer, L.J. et al. *Nature* 415(6871): 530–536 (2002).
- Parker, J.S. et al. *J Clin Oncol* 27(8): 1160–1167 (2009).
- Cardoso, F. et al. *Ann Oncol* 30(8): 1194–1220 (2019).
- Guerrero-Zotano, A.L. et al. *Clin Cancer Res* 24(11): 2517–2529 (2018).
- Mercogliano, M.F. et al. *Clin Cancer Res* 23(3): 636–648 (2017).
- Guardia, C. et al., *Clin Cancer Res* 27(18): 5096–5108 (2021).
- Sonnenblick, A. et al. *BMC Med* 13:177 (2015).
- Wolf, D. M. et al. *Cancer Cell* 40: 609–623.e6 (2022).
- Ma, C.X. et al. *Clin Cancer Res* 23(15): 4055–4065 (2017).
- Loi, S. et al. *PNAS* 107(22): 10208–10213 (2010).
- Foekens, J.A. et al. *Cancer Res.* 61: 1421–1425 (2001).
- Mackey, J.R. et al. *Clin Cancer Res.* 8(1): 110–116 (2002).
- Yang, V. et al. *RSC Med Chem.* 11(6): 646–664 (2020).
- Filippone, M.G. et al. *Nat Commun.* 13(1): 2642 (2022).
- Rodrigues-Ferreira, S. et al. *Proc Natl Acad Sci USA* 116(47): 23691–23697 (2019).
- Hatzis, C. et al. *JAMA* 305(18):1873–81 (2011).
- Karn, T. et al. *Clin Cancer Res* 26: 1896–1904 (2020).
- Modi, S. et al. *N Engl J Med* 387: 9–20 (2022).
- Michaleas, S. et al. *ESMO Open* 7 (2022).